APLS
$31.37
Apellis Pharmaceuticals
($.63)
(1.97%)
APLS
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($1.73)
Revenue:  $10.56 Mil
Monday
Nov 1
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when APLS reports earnings?
Beat
Meet
Miss

Where is APLS's stock price going from here?
Up
Flat
Down
Stock chart of APLS
Analysts
Summary of analysts' recommendations for APLS
Score
Grade
Pivots
Resistance
$33.11
$32.52
$31.95

$31.36

Support
$30.79
$30.20
$29.63
Tweet
Growth
Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States.